A prospective and retrospective multicenter cohort study of hepatocellular carcionoma development in patients after hepatitis C virus eradicatio
Not Applicable
- Conditions
- Patients after eradication of hepatitis C virus
- Registration Number
- JPRN-UMIN000023997
- Lead Sponsor
- Department of Gastroenterology, Graduate School of Medicine, the University ofTokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who developed hepatocellular carcinoma before achieved sustained virological response. 2) Patients with hepatitis B virus or human immunodeficiency virus co-infection. 3) Patients who physicians considered unsuitable for this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive hepatocellular carcinoma recurrence after hepatitis C virus eradication in the SMART-C V4 cohort study?
How does the SMART-C V4 observational trial compare with standard-of-care monitoring for hepatocellular carcinoma in post-hepatitis C patients?
Which biomarkers are associated with hepatocellular carcinoma risk stratification in patients with hepatitis C virus eradication?
What are the potential adverse events and management strategies for hepatocellular carcinoma surveillance in SMART-C V4 cohort?
What combination therapies or alternative approaches show promise in preventing hepatocellular carcinoma post-hepatitis C virus eradication compared to SMART-C V4?